RapaLink-1, a third-generation mTOR inhibitor capable of crossing the blood–brain barrier, was shown to be more potent in in vitro and in vivo GBM models than earlier generation mTOR inhibitors [25]. This evidence concerns the gene MTOR and glioblastoma.